Showing results (21-30 of 151) with videos related to
Sort By:
Pageof 16
Cytokine & Growth Factor Reviews|March 1, 2005
Tumor therapeutics by design: targeting and activation of death receptorsHarald Wajant, Jeannette Gerspach, Klaus PfizenmaierMethods in Molecular Biology (Clifton, N.J.)|November 13, 2020
Analysis of Ligand-Receptor Interactions Using Bioluminescent TNF Superfamily (TNFSF) Ligand Fusion ProteinsKirstin Kucka, Juliane Medler, Harald WajantFrontiers in Cell and Developmental Biology|November 29, 2023
Fn14 and TNFR2 as regulators of cytotoxic TNFR1 signalingDaniela Siegmund, Olena Zaitseva, Harald WajantCancer Letters|January 18, 2011
Engineering death receptor ligands for cancer therapyHarald Wajant, Jeannette Gerspach, Klaus PfizenmaierBiofactors (Oxford, England)|June 2, 2009
Improving TNF as a cancer therapeutic: tailor-made TNF fusion proteins with conserved antitumor activity and reduced systemic side effectsJeannette Gerspach, Klaus Pfizenmaier, Harald WajantThe FEBS Journal|November 20, 2016
Cell death-independent activities of the death receptors CD95, TRAILR1, and TRAILR2Daniela Siegmund, Isabell Lang, Harald WajantBiochemical and Biophysical Research Communications|September 28, 2005
Interferons induce proteolytic degradation of TRAILR4Andreas Wicovsky, Daniela Siegmund, Harald WajantCancers|August 26, 2022
TNF Receptor Associated Factor 2 (TRAF2) Signaling in CancerDaniela Siegmund, Jennifer Wagner, Harald WajantCytokine & Growth Factor Reviews|December 18, 2002
Non-apoptotic Fas signalingHarald Wajant, Klaus Pfizenmaier, Peter ScheurichRecent Patents on Anti-Cancer Drug Discovery|July 19, 2011
Therapeutic targeting of CD95 and the TRAIL death receptorsJeannette Gerspach, Klaus Pfizenmaier, Harald WajantPageof 16